학술논문
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4082-4082, 1p
Subject
Language
ISSN
0732183X